SCIVAX and Shin-Etsu Chemical Have Jointly Developed Amtelus ® , the World’s Smallest Light Source Device for 3D Sensors
SCIVAX Corporation (Head Office: Kawasaki, Japan; President: Satoru Tanaka; hereinafter, “SCIVAX”) and Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) have jointly developed Amtelus®, a light source device for 3D sensors and technology for its mass-production. The delivery of evaluation samples of Amtelus® will start in November 2024, and the sales of the products will be conducted by Shin-Etsu Chemical.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030531343/en/
World’s smallest light source module Amtelus® (Photo: Business Wire)
SCIVAX has so far sold Platanus®, an optical lens that diffuses and radiates light uniformly, as the 3D sensor light sources that are used in automotive and other various applications, contributing to improving sensor performance. Meanwhile, in recent years, the areas in which 3D sensing technology is utilized have grown wider, calling for light source devices to be more highly integrated and to have higher performance. However, it was difficult to reduce footprint using the conventional cavity structure, which posed one of the major unsolved issues.
To solve this issue, Shin-Etsu Chemical has developed a high-hardness material that can be processed by dicing, and that has both necessary optical properties and a sealing capability to protect devices. Using this material, SCIVAX has successfully developed Amtelus®, the world’s smallest light source device that incorporates the functions of Platanus®. This device has achieved a significantly smaller size compared with conventional devices having a mounting area of 1 mm2 or less, 10 times smaller than conventional devices, and with half or less of the thickness.
The main features of Amtelus® are as follows:
- Minimum size
It minimizes the mounting area of a light-emitting device, enabling its application in devices such as AR glasses and smartphones, for which installation has been difficult. In addition, using multiple Amtelus® modules can achieve more precise sensing. - Flexibility of light emission
The optical lens Platanus® can provide various types of irradiation fields with a high degree of design flexibility, enabling various types of irradiation, such as over a wide range of 140 degrees or more or with a high aspect ratio (120 deg × 30 deg). By using this technology, Amtelus® modules with various irradiation fields can be designed according to customers’ requests. - Cost competitiveness
By utilizing advanced nanoimprint mass production technology, the lenses are integrated with the light source in a resin package, which provides higher cost competitiveness compared to conventional products.
Shin-Etsu Chemical and SCIVAX are considering expanding the applications of this technology in the future to various fields, such as next-generation life science, mainly vital sensors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030531343/en/
Contacts
For inquiries about this matter, please contact:
SCIVAX Corporation
Optical device business Div.
Koichi Aida
Tel: +81-44-599-5051
https://www.scivax.com/en/inquiry/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.scivax.com
%2Fen%2Finquiry%2F&esheet=54145246&newsitemid=20241030531343&lan=en-US&anchor=ht
tps%3A%2F%2Fwww.scivax.com%2Fen%2Finquiry%2F&index=2&md5=48757c993876c6eb03fa2c2
8fb59b362
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: +81-3-6812-2340
https://www.shinetsu.co.jp/jp/inquiry/?d=shinetsu&t=shinetsu -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.shinetsu.c
o.jp%2Fjp%2Finquiry%2F%3Fd%3Dshinetsu%26t%3Dshinetsu&esheet=54145246&newsitemid=
20241030531343&lan=en-US&anchor=https%3A%2F%2Fwww.shinetsu.co.jp%2Fjp%2Finquiry%
2F%3Fd%3Dshinetsu%26amp%3Bt%3Dshinetsu&index=3&md5=dcd0e5fe6573b41921a1150c5a1a9
419
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla and Long Tale Games Launch Charity Campaign With Life Is Feudal to Support Games for Change31.10.2024 15:00:00 EET | Press release
Xsolla, a global video game commerce company, has partnered with Long Tale Games to launch a charity campaign. 50% of the proceeds from the 3-month subscription package to Life is Feudal will be donatedto Games For Change. This initiative, running until December 31st, reflects Xsolla’s commitment to leveraging the power of gaming to drive positive change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241031878088/en/ (Graphic: Xsolla) The campaign offers players an exciting adventure in Life is Feudal: MMO and allows them to make a tangible impact. With half of each 3-month subscription supporting educational programs, civic engagement initiatives, and social impact projects, the campaign demonstrates how gaming can foster a better future through the power of play. Players are empowered to engage with a meaningful cause, proving that games are more than just entertainment—they are a way to support causes that matter. "Gamin
Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution31.10.2024 14:00:00 EET | Press release
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety. "Oncology and vaccine trials face significant challenges in recruiting diverse patients, ensuring rapid execution, and maintaining and monitoring patient safety," said Joseph Schmidt, chief operating officer, Medidata. "By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata’s vast experience
Hassana Investment Company and EIG Sign MoU for Strategic Collaboration on Middle East Infrastructure and Energy Transition Projects31.10.2024 14:00:00 EET | Press release
Hassana Investment Company (Hassana) and EIG, a leading institutional investor to the global energy and infrastructure sectors, have signed a memorandum of understanding (MoU) to collaborate on infrastructure and energy transition projects in the Middle East through EIG’s targeted US$1 billion dedicated regional fund in which Hassana is considering becoming an anchor investor with an allocation of up to US$250 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241029142798/en/ (Photo: Business Wire) The MoU underscores EIG’s and Hassana’s shared commitment to expand their local and regional infrastructure and energy transition investment portfolios. By fostering participation from international investors and boosting foreign direct investment, this partnership aims to support the Kingdom of Saudi Arabia’s Vision 2030 goals and the broader regional shift toward cleaner, sustainable energy solutions. The MoU was signed by
Kinaxis Announces Normal Course Issuer Bid31.10.2024 13:00:00 EET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “Exchange” or “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 6, 2024 and ending November 5, 2025, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,404,639 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 23, 2024. As of the close of business on October 23, 2024, the Company had 28,092,786 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates31.10.2024 12:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress. “Ensuring the success of our lead COMP360 program is our absolute priority. We remain confident that COMP360 can be an effective therapy for patients with serious mental illness and our focus on delivering new treatment options for patients living with treatment-resistant depression remains paramount,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “The shift in the phase 3 pivotal program timeline has forced us to look carefully at our operations and ensure that every resource is focused on this goal. As such, we have made the difficult decision to reduce our workforce and exit activities that are not directly tied to the completion of the trials, regulatory filing and commercialization if approved. These are neces
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom